Premium
Disease modelling using induced pluripotent stem cells: Status and prospects
Author(s) -
Pomp Oz,
Colman Alan
Publication year - 2013
Publication title -
bioessays
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 184
eISSN - 1521-1878
pISSN - 0265-9247
DOI - 10.1002/bies.201200088
Subject(s) - induced pluripotent stem cell , phenotype , disease , somatic cell , drug discovery , biology , computational biology , clinical phenotype , lineage (genetic) , human induced pluripotent stem cells , stem cell , neuroscience , bioinformatics , genetics , medicine , embryonic stem cell , gene , pathology
The ability to convert human somatic cells into induced pluripotent stem cells (iPSCs) is allowing the production of custom‐tailored cells for drug discovery and for the study of disease phenotypes at the cellular and molecular level. IPSCs have been derived from patients suffering from a large variety of disorders with different severities. In many cases, disease related phenotypes have been observed in iPSCs or their lineage‐specific progeny. Several proof of concept studies have demonstrated that these phenotypes can be reversed in vitro using approved drugs. However, several challenges must be overcome to take full advantage of this technology. Here, we highlight recent advances in the field and discuss the main challenges associated with this technology as it applies to disease modelling.